New drug combo shows promise against hard-to-treat breast cancer

NCT ID NCT04796623

Completed Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior treatment or none at all. The trial is complete, and results will help determine if this approach offers better disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER

Contacts and locations

Locations

Affiliated Tumor Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830000, China
Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400000, China
Gansu Provincial Hostipal

Lanzhou, Gansu, 730030, China
Guangdong General Hospital

Guangzhou, Guangdong, 510062, China
Guangxi Medical University Affiliated Tumor Hospital

Nanning, Guangxi, 530021, China
Harbin Medical University Affiliated Cancer Hospital

Harbin, Heilongjiang, 150000, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, 110042, China
Shanghai East Hospital

Shanghai, Shanghai Municipality, 200123, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510062, China
The Fifth Medical Center of PLA General Hospital

Beijing, Beijing Municipality, 100039, China
The First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Xi'an Jiao Tong University

Xi’an, Shanxi, 710061, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050011, China
The Second Affiliated Hospital of PLA Air Force Military Medical University

Xi’an, Shanxi, 710038, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, 116027, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.